Aug. 4 at 5:17 PM
$ALT ALT management — take notes. This is how you raise money.
$ENTX just priced a
$275M oversubscribed placement at
$2.04, straight shares and pre-funded warrants, zero accompanying warrant coverage. No toxic overhang, no capped upside, no permanent overhang seller lurking for years. Compare that to ALT’s
$225M raise — a full 1:1 warrant tranche at
$3.00 that doesn’t clear until 45 days past Phase 3 MASH data. Same oversubscribed demand, wildly different discipline at the negotiating table.
Durso’s been touting “non-dilutive funding” and partnership options for months — I hope this time he actually delivers, because the last raise sure didn’t look like it!
https://finance.yahoo.com/healthcare/articles/entera-bio-announces-pricing-oversubscribed-123000084.html
